Display options
Cite
Lu Y, Wang JC, Zeng R, et al. Quantitative Comparison Of Microvascular Metrics On Three Optical Coherence Tomography Angiography Devices In Chorioretinal Disease. Clin Ophthalmol. 2019;13:2063-2069doi: 10.2147/OPTH.S215322.
Lu, Y., Wang, J. C., Zeng, R., Katz, R., Vavvas, D. G., Miller, J. W., & Miller, J. B. (2019). Quantitative Comparison Of Microvascular Metrics On Three Optical Coherence Tomography Angiography Devices In Chorioretinal Disease. Clinical ophthalmology (Auckland, N.Z.), 132063-2069. https://doi.org/10.2147/OPTH.S215322
Lu, Yifan, et al. "Quantitative Comparison Of Microvascular Metrics On Three Optical Coherence Tomography Angiography Devices In Chorioretinal Disease." Clinical ophthalmology (Auckland, N.Z.) vol. 13 (2019): 2063-2069. doi: https://doi.org/10.2147/OPTH.S215322
Lu Y, Wang JC, Zeng R, Katz R, Vavvas DG, Miller JW, Miller JB. Quantitative Comparison Of Microvascular Metrics On Three Optical Coherence Tomography Angiography Devices In Chorioretinal Disease. Clin Ophthalmol. 2019 Oct 22;13:2063-2069. doi: 10.2147/OPTH.S215322. eCollection 2019. PMID: 31749603; PMCID: PMC6816077.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2019 Oct 22;13:2063-2069. doi: 10.2147/OPTH.S215322. eCollection 2019.

Quantitative Comparison Of Microvascular Metrics On Three Optical Coherence Tomography Angiography Devices In Chorioretinal Disease.

Clinical ophthalmology (Auckland, N.Z.)

Yifan Lu, Jay C Wang, Rebecca Zeng, Raviv Katz, Demetrios G Vavvas, Joan W Miller, John B Miller

Affiliations

  1. Department of Ophthalmology, Harvard Medical School, Boston, Ma, USA.
  2. Harvard Retinal Imaging Laboratory, Massachusetts Eye and Ear, Boston, Ma, USA.
  3. Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

PMID: 31749603 PMCID: PMC6816077 DOI: 10.2147/OPTH.S215322

Abstract

PURPOSE: Optical coherence tomography angiography (OCT-A) has emerged as a novel tool for the non-invasive imaging and evaluation of the retinal microvasculature. There is little existing literature that compares OCT-A microvasculature metrics across different OCT-A devices in chorioretinal diseases. Herein, we examined these metrics on three available OCT-A platforms.

PATIENTS AND METHODS: All subjects were scanned on each of three OCT-A devices: Optovue Avanti Angiovue, Topcon DRI-OCT Triton Swept-Source OCT, and Zeiss Cirrus 5000-HD-OCT Angioplex. Two investigators independently measured foveal avascular zone (FAZ) area. Superficial capillary plexus (SCP) and deep capillary plexus (DCP) vessel densities (VD) were calculated from binarized images with ImageJ software. Image quality across devices was qualitatively compared. Interclass correlation coefficient (ICC), Bland-Altman analysis, repeated measures ANOVA, and post-hoc tests were performed for statistical analysis.

RESULTS: Thirteen eyes of seven patients with chorioretinal diagnoses were reviewed. ICC for FAZ measurement was 0.95. There was no significant difference in FAZ area across the three devices (p= 0.792). There was a significant difference in the SCP VD between the OCT-A devices (Triton 0.344 ± 0.013, Angiovue 0.323 ± 0.013, Angioplex 0.367 ± 0.014, p < 0.05). Significantly greater DCP VD was observed with Angioplex (0.385 ± 0.010) in comparison to both Triton (0.331 ± 0.009) and Angiovue (0.341 ± 0.020). A comparison of image quality revealed that Angiovue gives the highest quality, followed by Angioplex and Triton.

CONCLUSION: Core macular microvasculature metrics are now readily accessible on a variety of available OCT-A devices. While the FAZ can be reliably measured across all three devices in this study, there were significant differences for the vessel density in both the SCP and DCP. As a result, clinicians should be careful when comparing microvasculature metrics across different devices when using patient data in multicenter research investigations and clinical trials.

© 2019 Lu et al.

Keywords: Angioplex; Angiovue; OCTA; Optovue; Triton; Zeiss

Conflict of interest statement

Dr Joan W Miller reports personal fees from Amgen, Inc., KalVista Pharmaceuticals, Ltd., Alcon Research Institute, Genentech/Roche, Bausch + Lomb, Sunovion, Valeant Pharmaceuticals/Massachusetts Eye a

References

  1. Clin Ophthalmol. 2018 Dec 31;13:95-105 - PubMed
  2. Retina. 2010 Oct;30(9):1333-49 - PubMed
  3. Retina. 2015 Nov;35(11):2323-31 - PubMed
  4. PLoS One. 2017 May 10;12(5):e0177059 - PubMed
  5. Dev Ophthalmol. 2016;56:91-100 - PubMed
  6. Ophthalmology. 2015 Nov;122(11):2261-9 - PubMed
  7. Retina. 1990;10(1):1-8 - PubMed
  8. Ophthalmic Surg Lasers Imaging Retina. 2017 May 1;48(5):385-391 - PubMed
  9. Ophthalmic Surg Lasers Imaging Retina. 2018 Nov 1;49(11):e198-e205 - PubMed
  10. Ophthalmic Surg Lasers Imaging Retina. 2015 Sep;46(8):796-805 - PubMed
  11. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4729-37 - PubMed
  12. Clin Exp Ophthalmol. 2018 Mar;46(2):189-200 - PubMed
  13. PLoS One. 2018 Oct 18;13(10):e0206045 - PubMed
  14. Am J Ophthalmol. 2018 Feb;186:25-31 - PubMed
  15. Case Rep Ophthalmol Med. 2018 Jun 6;2018:7140164 - PubMed
  16. J Ophthalmic Vis Res. 2018 Jul-Sep;13(3):260-265 - PubMed
  17. Br J Ophthalmol. 2018 Aug;102(8):1141-1146 - PubMed
  18. PLoS One. 2018 Jun 28;13(6):e0199793 - PubMed
  19. JAMA Ophthalmol. 2015 Jan;133(1):45-50 - PubMed
  20. Ophthalmology. 2016 Dec;123(12):2498-2508 - PubMed

Publication Types